SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Parker-Hannifin drew down $7.75 billion in aggregate principal ($5.25 billion under a 364-Day Term Loan and $2.50 billion under a Three-Year Term Loan) on August 13, 2026, to finance the consummation of the Filtration Group acquisition.
View raw filing on EDGAR →This is a press release announcing Eikon Therapeutics' second quarter 2026 financial results, including R&D expenses ($75.5M), G&A expenses ($17.9M), net loss ($88.4M), and cash position ($531.2M as of June 30, 2026). The disclosure is furnished under Item 2.02 (Results of Operations and Financial Condition) and includes both financial metrics and clinical/corporate updates. This is a standard quarterly earnings release material to investors assessing the company's financial condition and cash runway.
View raw filing on EDGAR →ONE Gas completed a public offering of $375 million in 5.45% Senior Notes due 2036 on August 13, 2026, pursuant to an underwriting agreement entered into on August 11, 2026. Proceeds will be used for repayment of existing debt and general corporate purposes.
View raw filing on EDGAR →4DMT disclosed its Q2 2026 financial results via a press release furnished as Exhibit 99.1 under Item 2.02. The filing includes a complete Statements of Operations showing revenue of $3.8 million, R&D expenses of $68.3 million, and a net loss of $72.9 million for the three months ended June 30, 2026, along with balance sheet data and cash position information. This is a standard quarterly earnings release for a public biotechnology company.
View raw filing on EDGAR →Lithium Americas completed the initial closing of a $150 million subordinated convertible debenture issuance to YA II PN, Ltd. on August 13, 2026, with an additional $25 million available in delayed closings. The debentures carry a 5% base interest rate (escalating to 7.5% or 15% under specified conditions), a 5-year maturity, and conversion rights into common shares, subject to significant covenants and restrictions on repayment, additional indebtedness, and equity issuances.
View raw filing on EDGAR →Lithium Americas issued common shares and convertible debentures to YA II PN, Ltd. pursuant to a Purchase Agreement, relying on Section 4(a)(2) exemption from registration. The issuance of equity and equity-linked securities constitutes a dilutive capital raise material to investors assessing ownership structure and shareholder dilution.
View raw filing on EDGAR →Midera Food Processing issued its Q2 2026 earnings release (quarter ended July 4, 2026) reporting net sales of $245.4 million (up 13.2% year-over-year), net earnings of $10.8 million, and raised full-year 2026 guidance. This is the company's first earnings report as an independent public company following its July 6, 2026 separation from Middleby.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including R&D expenses ($18.2M), G&A expenses ($4.6M), net loss ($31.6M or $0.27 per share), and cash position ($88.8M), along with business highlights regarding tegoprubart clinical development. The filing explicitly states it is "furnished to comply with Item 2.02 of Form 8-K" and includes condensed consolidated financial statements.
View raw filing on EDGAR →The filing discloses Genasys Inc.'s fiscal Q3 2026 financial results for the quarter ended June 30, 2026, issued via press release on August 13, 2026. The disclosure includes revenue ($7.3M vs. $9.9M prior year), gross margin (57.1% vs. 26.3%), GAAP net loss ($4.7M vs. $6.5M), and EPS ($0.10 loss vs. $0.14 loss), along with consolidated balance sheet and statements of operations. This is a standard quarterly earnings release material to investors' assessment of the company's financial performance and condition.
View raw filing on EDGAR →This is a clear earnings release disclosing Arcadia Biosciences' financial results for Q2 and H1 2026. The press release (Exhibit 99.1) announces quarterly revenues, operating expenses, net loss per share, and cash position, with supporting financial statements (balance sheet, income statement, cash flow statement) in Exhibit 99.2. The Item 2.02 disclosure and attached exhibits are the standard format for quarterly earnings announcements.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026. The filing discloses financial results including cash position ($57.2 million), R&D expenses ($2.8 million), G&A expenses ($2.4 million), and net loss ($4.7 million or $(0.04) per share), along with condensed consolidated balance sheets and statements of operations. The press release is attached as Exhibit 99.1 and filed under Item 2.02, which is the standard Item for results of operations and financial condition disclosures.
View raw filing on EDGAR →This is a clear earnings release disclosing GrabAGun's preliminary financial results for Q2 2026 (three and six months ended June 30, 2026). The press release reports net revenues of $23.2 million (up 9.4% YoY), gross profit margin expansion to 13.5%, and net loss of $1.8 million for the quarter. The filing explicitly incorporates the press release by reference under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The disclosure includes detailed financial statements and operational metrics that would materially affect a reasonable investor's assessment of the company's performance.
View raw filing on EDGAR →This is a standard earnings release disclosing Q2 2026 financial results for Invivyd, Inc., including PEMGARDA net product revenue of $14.3 million (21% growth YoY), R&D expenses of $29.4 million, SG&A expenses of $29.5 million, and a net loss of $44.4 million. The press release also highlights recent business developments including clinical trial progress on VYD2311. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →Item 2.02 discloses Rani Therapeutics' financial results for the three and six months ended June 30, 2026, including a press release furnished as Exhibit 99.1. The filing reports contract revenue of $1.7 million (Q2 2026 vs. $0 in Q2 2025), net loss of $8.4 million (Q2 2026 vs. $11.2 million in Q2 2025), and cash position of $53.4 million as of June 30, 2026. This is a standard quarterly earnings disclosure with consolidated financial statements and operational metrics material to investor assessment of the company's financial condition and progress.
View raw filing on EDGAR →Assembly Biosciences issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including revenue of $13.4 million, R&D expenses of $14.9 million, and a net loss of $3.9 million ($0.20 per share). The filing includes condensed consolidated balance sheets and statements of operations with comparative periods, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →This Item 2.02 discloses Celcuity's financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The filing reports net loss of $78.9 million ($1.44 per share) versus $45.3 million ($1.04 per share) in the prior year, along with operating expenses, R&D and SG&A breakdowns, and cash position. This is a standard quarterly earnings release disclosure, material to investors assessing the company's financial performance and cash runway (expected to finance operations into 2029).
View raw filing on EDGAR →Accelerant Holdings entered into an Agreement and Plan of Merger with Cherry Tree BidCo (affiliated with Thoma Bravo Discover Fund V) on August 13, 2026, whereby the Company will merge with and become a wholly owned subsidiary of Parent. The merger consideration is $20.25 per share plus a potential ticking amount. This is a material acquisition/change of control transaction requiring shareholder approval and resulting in delisting from NYSE, clearly falling under Item 1.01 (Entry into a Material Definitive Agreement) and the ma_activity event type.
View raw filing on EDGAR →The press release announces entry into a share swap agreement on August 12, 2026, whereby Masonglory acquires a 20% equity interest in Beta Beteiligungs und Besitz GmbH (a private Austrian construction materials trading company) in exchange for 1,377,000 Class A ordinary shares valued at approximately $4.68 million. This constitutes a material acquisition of an equity interest in a target company with a stated 100% valuation of $23.4 million, representing a horizontal, synergistic expansion into Continental Europe. The transaction is a discrete M&A event requiring disclosure under Item 1.01 (Material Agreements) or Item 2.01 (Completion of Acquisition or Disposition).
View raw filing on EDGAR →The 8-K discloses under Item 2.02 (Results of Operations and Financial Condition) that AleAnna issued a press release on August 13, 2026 announcing financial results for Q2 2026. The press release reports net income of $3.8 million and Adjusted EBITDA of $4.1 million for the quarter, along with detailed consolidated statements of operations and balance sheets. This is a standard quarterly earnings release, material to investors assessing the company's financial performance and operational progress at its Longanesi and Gradizza production assets.
View raw filing on EDGAR →Chicago Atlantic BDC issued a press release on August 13, 2026 announcing its financial results for the second quarter ended June 30, 2026, including net investment income of $7.7 million ($0.34 per share), operating highlights, balance sheet data, and portfolio activity. The earnings presentation was disseminated in connection with a conference call on the same date.
View raw filing on EDGAR →The filing discloses that the Selection Committee declared void the first call for a selection process to appoint a valuation entity for determining the minimum price in a tender offer by Holcim Ltd. for Cementos Pacasmayo's common shares. This is a material procedural development in an ongoing M&A transaction (tender offer) that would affect investor assessment of the acquisition timeline and process.
View raw filing on EDGAR →This press release announces Cellebrite's second-quarter 2026 financial results, including ARR of $507.8M (up 21% YoY), revenue of $131.1M (up 16% YoY), and adjusted EBITDA of $31.8M. While the release also discloses a CEO succession (Shiven Ramji succeeding Thomas E. Hogan), the primary substance is the earnings announcement with detailed financial metrics and forward guidance. The company explicitly "lowered full-year 2026 ARR and revenue outlook" while raising adjusted EBITDA targets, making the financial results the dominant disclosure. The CEO transition, though material, is secondary to the earnings content.
View raw filing on EDGAR →This is a news release dated August 13, 2026, announcing Telesat's financial results for the three and six months ended June 30, 2026. The exhibit discloses consolidated revenue of $79 million (Q2 2026) and $167 million (H1 2026), adjusted EBITDA figures, net losses, and segment performance, along with balance sheet data and forward guidance. This is a classic earnings release announcing periodic financial results, material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →Bluejay Diagnostics disclosed Q2 2026 financial results for the quarter ended June 30, 2026, reporting a cash position of $9.6 million at quarter-end (versus $5.2 million at year-end 2025) and $7.7 million net cash from financing activities in H1 2026, along with operational progress on the Symphony IL-6 platform.
View raw filing on EDGAR →This is a Notice of Extraordinary General Meeting and proxy form for shareholder approval of multiple equity issuances totaling approximately $18.5 million, including placement shares, ADS shares, options, and warrants. While the document is primarily a governance/procedural notice, the underlying resolutions seek shareholder approval for material dilutive equity issuances (408.8M first-tranche placement shares, 384.5M ADS shares, 40M second-tranche shares, 448.8M placement options, 666.7M SPP shares and options, 200M shortfall options, 1.3M ADR warrants, and director/CEO equity grants). The aggregate capital raise of ~$18.5M and substantial share dilution would materially affect investor assessment. This is classified as governance_other rather than dilutive_issuance because the exhibit is the notice and proxy materials for the shareholder meeting itself, not a discrete announcement of the issuance; the actual issuances are contingent on shareholder approval at the meeting.
View raw filing on EDGAR →This is a clear earnings release disclosing financial results for Q2 2026 and six months ended June 30, 2026. The filing explicitly states "On August 13, 2026, DUKE Robotics Corp. issued a press release providing selected financial information for the three and six months ended June 30, 2026" under Item 2.02 (Results of Operations and Financial Condition), with the press release attached as Exhibit 99.1. The disclosure includes detailed revenue, cost of revenues, operating loss, net loss, and balance sheet information, along with business updates on expanded operations and strategic initiatives.
View raw filing on EDGAR →Veea Inc. entered into an At Market Issuance Sales Agreement (ATM Agreement) with Roth Capital Partners on August 13, 2026, authorizing the sale of up to $4,353,000 in common stock shares through an at-the-market offering under an existing Form S-3 registration statement. This is a classic dilutive equity issuance that would materially affect existing shareholders through potential dilution and is disclosed under Item 1.01 (Entry into a Material Definitive Agreement).
View raw filing on EDGAR →Item 2.02 discloses quarterly financial results for the period ended July 3, 2026, with a press release attached as Exhibit 99.1. The filing reports Q2 2026 revenue of $66.4 million (up 35.2% YoY), adjusted EBITDA of $8.9 million (up 57.9%), and record backlog of $131.5 million. This is a standard earnings release disclosure, material to investors assessing the registrant's financial performance and operational momentum.
View raw filing on EDGAR →The filing discloses NeuroOne's fiscal Q3 2026 financial results via press release dated August 13, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The press release reports product revenue of $2.0 million (16% YoY growth), gross margins expanding to 59.9%, and product orders of $2.7 million during the quarter, along with operational highlights including ISO 13485 certification and StereoCED platform development milestones. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and operational progress.
View raw filing on EDGAR →This press release announces progress on Eco Wave Power's 1 MW wave energy project in Porto, Portugal, specifically the official commencement of breakwater rehabilitation works by APDL and the CEO's planned meetings to coordinate installation timelines and grid-connection extensions. The disclosure is primarily operational—describing project advancement, infrastructure coordination, and subcontractor engagement—rather than a discrete financial event, M&A activity, or governance matter. It is material because it concerns a key commercial-scale deployment milestone for the company's core business strategy in a major European market.
View raw filing on EDGAR →SS Innovations International disclosed Q2 and H1 2026 financial results via press release dated August 13, 2026, reporting record quarterly revenue of $13.9 million (up 39.4% year-over-year), along with gross profit, net loss, and operational metrics including SSi Mantra installations and cumulative surgeries.
View raw filing on EDGAR →The press release announces a corporate name change from Brenmiller Energy Ltd. to BrenX Ltd., effective August 11, 2026, with a corresponding Nasdaq ticker symbol change from BNRG to BRNX effective August 14, 2026. While the announcement emphasizes strategic expansion into integrated industrial energy solutions, the core disclosed action is a formal corporate name and ticker change—a governance matter. The strategic narrative is forward-looking context, but the material disclosure is the name change itself and its operational consequences (ticker change, new website).
View raw filing on EDGAR →Evolution Metals & Technologies Corp. appointed General Thomas A. Bussiere (ret.) as an independent director and member of the Audit, Compensation, and Nominating and Corporate Governance Committees, effective August 13, 2026. General Bussiere brings 40 years of Air Force leadership experience, including command of Air Force Global Strike Command overseeing 33,000+ personnel and multi-billion-dollar programs.
View raw filing on EDGAR →The filing discloses a Nasdaq minimum bid price compliance matter under Listing Rule 5550(a)(2). Although the Company has now regained compliance as of August 10, 2026, the disclosure documents the prior delisting risk period (November 2025 through August 2026) during which the stock failed to meet the $1 minimum bid price requirement and the Company was subject to two successive 180-day compliance periods. This is a material delisting-risk event, even though the immediate threat has been resolved.
View raw filing on EDGAR →TMRC completed a merger in which its shareholders received USAR Common Stock at a fixed exchange ratio of 0.043279843 shares per TMRC share, resulting in a change of control and the conversion of TMRC into a subsidiary of USAR. The merger also involved termination of TMRC's material mineral exploration and option agreement with Santa Fe Gold Corporation and extinguishment of TMRC shareholders' rights, with shareholders retaining only the right to receive merger consideration.
View raw filing on EDGAR →TMRC's common stock was withdrawn from OTCQB trading, and the company announced its intention to file Form 15 for deregistration under Section 12(g) and suspension of SEC reporting obligations.
View raw filing on EDGAR →This is a clear earnings release disclosing Presidio Production Company's second quarter 2026 financial results, including net income of $14.4 million ($0.34 per Class A share), total revenue of $54.0 million, and Adjusted EBITDA of $33.2 million. The press release, dated August 11, 2026 and attached as Exhibit 99.1, is the primary disclosure under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for quarterly earnings announcements.
View raw filing on EDGAR →The filing discloses the appointment of Lee McIntire as Chief Executive Officer effective August 11, 2026. While the disclosure also includes compensatory details (base salary of $750,000, annual bonus eligibility, $15,000 monthly housing allowance, and a $3,000,000 RSU grant), the principal action is the appointment of a named executive to a C-suite role. The appointment of a CEO is a material governance event affecting investor assessment of company leadership.
View raw filing on EDGAR →Zoomcar entered into securities purchase agreements on July 27, 2026, issuing 498 Series A Convertible Preferred Shares and 498 Warrants (exercisable for 9.96 million common shares) in a private placement under Section 4(a)(2) and Regulation D Rule 506(c), with up to $5 million in units plus a $5 million overallotment option. The offering includes unregistered sales of Units, Preferred Shares, Warrants, and Placement Agent Warrants, with significant potential dilution to existing shareholders through conversion and warrant exercise rights.
View raw filing on EDGAR →Zoomcar held its 2026 Annual Meeting of Stockholders on August 11, 2026, with stockholder approval of six proposals: ratification of auditors, authorization to increase authorized common shares from 250 million to 1.99 billion, approval of a warrant exchange offer for up to 509 million shares, a restricted stock grant to Chairman Uri Levine, authorization for a reverse stock split, and meeting adjournment. All proposals passed, reflecting material shareholder approval of significant capital structure changes and executive compensation.
View raw filing on EDGAR →Profusa implemented a 1-for-4 reverse stock split of its common stock, effective August 17, 2026, pursuant to an amendment to its certificate of incorporation filed with Delaware. The reverse split consolidates every four shares into one share, reducing outstanding shares from approximately 2,422,906 to 605,726, and was approved by stockholders at the June 23, 2026 annual meeting.
View raw filing on EDGAR →This is a news release announcing DEFSEC's third quarter fiscal 2026 financial results, including revenue of $2.7M (up 92% YoY), gross margin improvement to 33.1% from 28.2%, and cash position of $5.8M. The release explicitly states it is a summary of Q3 Fiscal 2026 results and references the unaudited condensed consolidated interim financial statements filed on SEDAR+ and EDGAR. This is a discrete earnings announcement, not a periodic financial report itself, and would materially affect a reasonable investor's assessment of the company's financial performance and growth trajectory.
View raw filing on EDGAR →This is a news release dated August 13, 2026, announcing DeFi Technologies' second quarter 2026 financial results. The exhibit discloses revenue of $7.8 million, operating loss of $2.3 million, detailed segment performance (Valour AUM, net inflows, and Stillman Digital revenue), and balance sheet metrics including $135 million in combined cash, treasury, and venture portfolio value. The release includes CEO commentary and a shareholder call announcement, all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →The Board of Directors approved a declaration of Interest on Equity (a form of dividend distribution) in the gross amount of R$706,000,000.00 based on retained earnings, with a record date of April 29, 2026 and payment date of September 30, 2026. This is a material capital distribution to shareholders that would affect investor assessment of the company's capital allocation and shareholder returns.
View raw filing on EDGAR →The filing discloses Board approval of cancellation of 279 million treasury shares (1.8% of outstanding shares) and completion of a share buyback program. While technically a capital reduction rather than a dividend, share cancellations following buyback programs are economically equivalent to distributions—they reduce share count and increase per-share value for remaining shareholders. The materiality and scale (279 million shares) warrant classification as a capital distribution event.
View raw filing on EDGAR →Embraer's Board of Directors declared Interest on Equity (IoE) of R$ 154,000,000.00 (R$ 0.21634283532 per ordinary share) for the 3rd quarter of fiscal year 2026, with a payment deadline of May 24, 2027. This is a distribution to shareholders and qualifies as a dividend distribution under the taxonomy. The amount is material and would affect investor assessment of capital allocation and shareholder returns.
View raw filing on EDGAR →CapsoVision entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald for an at-the-market offering program permitting sale of up to $100 million in common stock, representing a material capital-raising mechanism that will dilute existing shareholders.
View raw filing on EDGAR →CapsoVision issued a press release announcing financial results for the fiscal quarter ended June 30, 2026, including quarterly revenue of $3.6 million (up 10% YoY), gross profit, operating expenses, net loss of $7.5 million, and per-share metrics, along with condensed financial statements.
View raw filing on EDGAR →Brian Yoor resigned from his position as a Board member and Audit Committee chair effective August 12, 2026. While the filing also mentions Karen McGinnis's appointment as the new Audit Committee chair, the principal disclosed action centers on Yoor's departure. Board resignations, particularly from audit committee leadership, are material governance events affecting investor assessment of the company's oversight structure.
View raw filing on EDGAR →CorMedix issued a press release on August 13, 2026, announcing Q2 2026 financial results including consolidated revenue of $101.9 million, net income of $26.0 million, and adjusted EBITDA of $58.7 million, along with updated full-year 2026 guidance. The disclosure is a standard quarterly earnings announcement furnished as Exhibit 99.1 under Item 2.02, with detailed financial statements and business highlights.
View raw filing on EDGAR →